Histone deacetylase inhibitors (HDACi) are a relatively new and promising class of drugs in the therapy of malignant diseases. They could demonstrate antiproliferative and proapoptoic effects on various tumours and cause changes in gene ecpression patterns in treated cells. In this thesis the in vitro and in vivo efficiency of the classic HDACi butyrate and its prodrug tributyrin on prostate cancer cells LNCaP and PC-3 were investigated. Methods: In vitro cell culture experiments were performed with focus on changes in cell morphology, proliferation and apoptosis. For in vivo testing tumour cells were seeded on chicken egg chorionallantois membrane (CAM) to analyze apoptosis rate and implanted in a xenograft model using nude mice for assesm...
The main goal of our study has been to analyze the efficiency of new anticancer drugs, specifically ...
Epigenetic dysregulations are linked to many human diseases including neurodegenerative disorders, i...
Androgen receptor-negative (AR-) prostate tumours are observed in 11-24% of prostate cancer patients...
Hepatocellular carcinoma (HCC) ranks in prevalence and mortality among top 10 cancers worldwide. But...
Hepatocellular carcinoma (HCC) ranks in prevalence and mortality among top 10 cancers worldwide. But...
[[abstract]]Purpose: To assess the antitumor effects of a novel phenylbutyrate-derived histone deace...
[[abstract]]Purpose: To assess the antitumor effects of a novel phenylbutyrate-derived histone deace...
Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological ...
BACKGROUND: Sodium butyrate, a histone deacetylase inhibitor, has emerged as a promising anticancer ...
<div><p>Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with...
Background: Sodium butyrate, a histone deacetylase inhibitor, has emerged as a promising anticancer ...
Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with antican...
Sodium butyrate, a histone deacetylase inhibitor, has emerged as a promising anticancer drug for mul...
Sodium butyrate, a histone deacetylase inhibitor, has emerged as a promising anticancer drug for mul...
Histone deacetylase inhibitors (HDACi) can elicit a range of biological responses that affect tumor ...
The main goal of our study has been to analyze the efficiency of new anticancer drugs, specifically ...
Epigenetic dysregulations are linked to many human diseases including neurodegenerative disorders, i...
Androgen receptor-negative (AR-) prostate tumours are observed in 11-24% of prostate cancer patients...
Hepatocellular carcinoma (HCC) ranks in prevalence and mortality among top 10 cancers worldwide. But...
Hepatocellular carcinoma (HCC) ranks in prevalence and mortality among top 10 cancers worldwide. But...
[[abstract]]Purpose: To assess the antitumor effects of a novel phenylbutyrate-derived histone deace...
[[abstract]]Purpose: To assess the antitumor effects of a novel phenylbutyrate-derived histone deace...
Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological ...
BACKGROUND: Sodium butyrate, a histone deacetylase inhibitor, has emerged as a promising anticancer ...
<div><p>Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with...
Background: Sodium butyrate, a histone deacetylase inhibitor, has emerged as a promising anticancer ...
Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with antican...
Sodium butyrate, a histone deacetylase inhibitor, has emerged as a promising anticancer drug for mul...
Sodium butyrate, a histone deacetylase inhibitor, has emerged as a promising anticancer drug for mul...
Histone deacetylase inhibitors (HDACi) can elicit a range of biological responses that affect tumor ...
The main goal of our study has been to analyze the efficiency of new anticancer drugs, specifically ...
Epigenetic dysregulations are linked to many human diseases including neurodegenerative disorders, i...
Androgen receptor-negative (AR-) prostate tumours are observed in 11-24% of prostate cancer patients...